Pricing Log in Create free account
Saturday 17 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

255.55 2.27 +0.90%
Market cap
$610.4B
P/E
29.6×
Fwd P/E
24.9×
Dividend yield
2.07%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Johnson & Johnson (JNJ) Debt to equity

Alert me on Debt to equity

Johnson & Johnson's debt to equity at the end of the quarter to 30 June 2026 was 0.4×, down 0.0× from fiscal 2025 (0.5×). Over the past ten years it has ranged from 0.2× (fiscal 2015) to 0.5× (fiscal 2020); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.5× 12.81%
FY2024 0.4× 13.93%
FY2023 0.4× 7.48%
FY2022 0.4× (13.58%)
FY2021 0.4× (21.45%)
FY2020 0.5× 15.76%
FY2019 0.4× (3.84%)
FY2018 0.5× (9.14%)
FY2017 0.5× 59.99%
FY2016 0.3× 76.37%

Quarterly newest first

Period Debt to equity Change
Jun 2026 0.4× (4.91%)
Mar 2026 0.5× (4.43%)
Dec 2025 0.5× (2.72%)
Sep 2025 0.5× (0.58%)
42 more quarters

Against its own ten years

Low 0.2× High 0.5×
Ten-year median 0.4×
Current reading's percentile 82

Debt to equity against peers

Company Debt to equity
ABBV AbbVie Inc. compare −12.0×
JNJ Johnson & Johnson 0.4×
AZN AstraZeneca PLC compare 0.6×
PFE Pfizer Inc. compare 0.7×
NVS Novartis AG compare 1.1×
MRK Merck & Co., Inc. compare 1.2×
LLY Eli Lilly and Company compare 1.6×
GILD Gilead Sciences, Inc. compare 2.2×
AMGN Amgen Inc. compare 4.9×
Drug Manufacturers General industry median 0.6×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on JNJ